Nektar Therapeutics buy BiotechBee
Start price
15.04.24
/
70%
€1.59
Target price
28.02.26
€2.40
Performance (%)
-24.69%
Price
22:26
€1.20
Summary
This prediction is currently active. The price of Nektar Therapeutics has decreased since the start of the prediction. Compared to the start price this results in a performance of -24.69%. This prediction currently runs until 28.02.26. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 70% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Nektar Therapeutics | 18.596% | 18.596% |
iShares Core DAX® | -1.471% | 1.895% |
iShares Nasdaq 100 | -0.486% | 4.395% |
iShares Nikkei 225® | -2.115% | 2.450% |
iShares S&P 500 | 0.394% | 3.118% |
According to BiotechBee what are the pros and cons of Nektar Therapeutics for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Nektar Therapeutics diskutieren
Buy mit Kursziel 2,4